IADR Abstract Archives

SAHA Sensitizes TRAIL-induced Apoptosis in Oral Cancer Cells through DR5

Objectives: Suberoylanilide hydroxamic acid (SAHA) has been shown to selectively induce tumor apoptosis in both cell cultures and animal models in several types of cancers and are regarding as a promising new class of chemotherapeutic agents. In this report, we pursued a detail investigation of the mechanism of SAHA-induced apoptosis and evaluated the ability of SAHA to sensitize TRAIL-induced apoptosis in TRAIL-resistant oral cancer cells.

Methods: The effects of SAHA on cell cycle and apoptosis of SAS (a TRAIL resistant human oral cancer cell) was examined using flow cytometry analysis, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay, DNA fragmentation assay and Western blotting.

Results: We found SAHA induced apoptosis in human oral cancer cells. Western blotting showed SAHA increased DR5 protein expression and activated caspase-8 and caspase-9. Human recombinant DR5/Fc chimera protein significantly inhibited apoptosis induced by SAHA. Subtoxic concentrations of SAHA sensitize SAS cells to exogenous recombinant TRAIL-induced apoptosis.

Conclusions: These results suggest that SAHA can induce apoptosis through activation of DR5/TRAIL death pathway. Combined treatment of SAHA and TRAIL may be used as a new promising therapy for oral cancer.


Division: Asia/Pacific Region Meeting
Meeting: 2009 Asia/Pacific Region Meeting (Wuhan, China)
Location: Wuhan, China
Year: 2009
Final Presentation ID: 734
Abstract Category|Abstract Category(s): Scientific Groups
Authors
  • Yeh, Cheng-chang  ( School of Dentistry, National Taiwan University, Taipei, N/A, Taiwan )
  • Deng, Yi-ting  ( School of Dentistry, National Taiwan University, Taipei, N/A, Taiwan )
  • Sha, De-yuan  ( School of Dentistry, National Taiwan University, Taipei, N/A, Taiwan )
  • Kuo, Mark Yen-ping  ( School of Dentistry, National Taiwan University, Taipei, N/A, Taiwan )
  • SESSION INFORMATION
    Oral Session
    Oral Session J (Oral Medicine & Pathology)
    09/24/2009